MaxCyte News and Activities

Presence

MaxCyte develops cell engineering technology for biotech and pharmaceutical research and manufacturing. Its products and services include electroporation platforms, workflow support, and licensing for companies developing cell therapies and biologics.

MaxCyte products and services overview:

Cell engineering platforms
Electroporation systems
Research instruments
Manufacturing support
Licensing services
Workflow software

Revenue: ~$36 million

Employees: 230

Headquarters: Rockville, United States (USA)

MaxCyte is owned by Casi Pharmaceuticals.

Casi Pharmaceuticals is a company listed under the stock ticker CASI (US).

Casi Pharmaceuticals has a direct presence in 2 countries.

They are in:

Pharmaceuticals67%
Biotechnology33%

Executives

View the org chart displaying its 24 main executives

Most searched biographies at MaxCyte

Popular executive movements at MaxCyte

Alfred Sloan, Senior Business Development Manager, has left the company (posted on March 23 2026).
Caleb Faboye, Head of Quality, has left the company (posted on March 23 2026).
Parmeet Ahuja will join the company as Chief Financial Officer on Mar. 30, 2026 (posted on March 23 2026).

Click here to view some more movements at MaxCyte

Popular executive movements at Casi Pharmaceuticals

Wei-Wu He who was Executive Chairman of the Board, becomes Director (posted on November 20 2025).
Barbara Krebs-Pohl has joined the company as Non Executive Board Member (posted on October 27 2025).
James Huang has joined the company as Director (posted on September 26 2025).

Create your alert
to follow the executive moves at MaxCyte.